Jazz Pharmaceuticals' essential tremor drug falls flat in Phase IIb trial [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
The Dublin, Ireland-based biopharma company announced top-line results from the multi-centre, double-blind trial (NCT05122650) evaluating the efficacy and safety of once-daily oral suvecaltamide in 420 patients. The high-dose cohort (30mg) failed to achieve the primary endpoint of change from baseline to week 12 on the Essential Tremor Rating Assessment Scale (TETRAS) and the key secondary endpoint of the Clinical Global Impression-Severity (CGI-S) scale. Data for the 10mg or 20mg cohorts has not yet been released. Although the data did not reach statistical significance, Jazz said there were numeric improvements observed on the primary endpoint and key secondary endpoint. There was also a more significant increase in improvement in the placebo cohort than expected, higher than that of the previous T-CALM trial (NCT03101241). Executive vice-president of Jazz Pharmaceuticals Rob Lannone said: "We are disappointed that the trial did not meet its primary endpoint. We recognise the
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals' (NASDAQ:JAZZ) earnings have declined over five years, contributing to shareholders 16% loss [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024PR Newswire
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $205.00 price target on the stock.MarketBeat
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock.MarketBeat
- Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024 [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 7/31/24 - Beat
JAZZ
Sec Filings
- 9/11/24 - Form 4
- 9/6/24 - Form 8-K
- 9/5/24 - Form 144
- JAZZ's page on the SEC website